Elevance Health, Inc. (NYSE:ELV) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Elevance Health, Inc. (NYSE:ELV) have been assigned a consensus rating of “Moderate Buy” from the twenty-three ratings firms that are covering the company, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $419.1579.

Several equities analysts have recently commented on ELV shares. Barclays increased their price objective on Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a research report on Tuesday, May 26th. UBS Group increased their price target on shares of Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research report on Friday, May 22nd. Jefferies Financial Group decreased their price target on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Mizuho lifted their price target on shares of Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a report on Monday, June 8th.

Insider Transactions at Elevance Health

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the sale, the director directly owned 10,734 shares in the company, valued at $4,312,599.18. This represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.34% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Elevance Health

A number of hedge funds and other institutional investors have recently modified their holdings of ELV. Wellington Management Group LLP grew its position in Elevance Health by 25.2% during the 4th quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company’s stock worth $2,906,051,000 after acquiring an additional 1,668,679 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Elevance Health by 27.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company’s stock valued at $2,610,261,000 after purchasing an additional 1,607,274 shares during the last quarter. Artisan Partners Limited Partnership lifted its position in Elevance Health by 10.0% in the fourth quarter. Artisan Partners Limited Partnership now owns 5,032,751 shares of the company’s stock valued at $1,764,231,000 after purchasing an additional 455,946 shares during the last quarter. First Eagle Investment Management LLC boosted its stake in shares of Elevance Health by 0.6% during the fourth quarter. First Eagle Investment Management LLC now owns 4,022,874 shares of the company’s stock valued at $1,410,219,000 after purchasing an additional 24,271 shares during the period. Finally, Invesco Ltd. grew its holdings in shares of Elevance Health by 50.3% in the fourth quarter. Invesco Ltd. now owns 3,903,878 shares of the company’s stock worth $1,368,505,000 after purchasing an additional 1,306,390 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Down 0.2%

Shares of NYSE:ELV opened at $416.97 on Friday. Elevance Health has a 52-week low of $273.71 and a 52-week high of $427.19. The firm has a fifty day moving average of $391.29 and a 200 day moving average of $351.14. The firm has a market capitalization of $90.55 billion, a PE ratio of 17.74, a price-to-earnings-growth ratio of 2.37 and a beta of 0.67. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the prior year, the firm earned $11.97 earnings per share. The firm’s revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, research analysts anticipate that Elevance Health will post 26.86 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th were paid a $1.72 dividend. The ex-dividend date of this dividend was Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.6%. Elevance Health’s payout ratio is currently 29.26%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.